These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21644867)

  • 1. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?
    Harvey KJ; Day RO; Campbell WG; Lipworth W
    Med J Aust; 2011 Jun; 194(11):567-8. PubMed ID: 21644867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer drug offers effective, cheaper option for AMD.
    Stephenson J
    JAMA; 2011 May; 305(20):2053-4. PubMed ID: 21610231
    [No Abstract]   [Full Text] [Related]  

  • 3. Macular degeneration, patients' groups, and pharma.
    The Lancet
    Lancet; 2007 Jul; 370(9583):194. PubMed ID: 17658373
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab and ranibizumab. Bevacizumab and the inverse postcode lottery.
    Harris MJ
    BMJ; 2010 Jul; 341():c3718. PubMed ID: 20627986
    [No Abstract]   [Full Text] [Related]  

  • 5. [Vision for patients with macular degeneration].
    Paukstadt W
    MMW Fortschr Med; 2007 Jan; 149(3):10-2. PubMed ID: 17619375
    [No Abstract]   [Full Text] [Related]  

  • 6. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?
    Ziemssen F; Grisanti S; Bartz-Schmidt KU; Spitzer MS
    Drugs Aging; 2009; 26(4):295-320. PubMed ID: 19476398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study aims to clarify efficacy, safety of eye drug treatments.
    Mitka M
    JAMA; 2007 Apr; 297(14):1538-9. PubMed ID: 17426265
    [No Abstract]   [Full Text] [Related]  

  • 8. [Age-related visual loss].
    Neubauer AS; Kernt M
    MMW Fortschr Med; 2013 Feb; 155(2):36-7. PubMed ID: 23573743
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of neovascular age-related macular degeneration with bevacizumab].
    Monzón Moreno A
    Farm Hosp; 2006; 30(6):387-8. PubMed ID: 17298199
    [No Abstract]   [Full Text] [Related]  

  • 10. A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
    Formoso G; Marata AM; Magrini N; Bero L
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):ED000090. PubMed ID: 25228121
    [No Abstract]   [Full Text] [Related]  

  • 11. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)].
    Holz FG
    MMW Fortschr Med; 2007 Jan; 149(3):13-4. PubMed ID: 17619376
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab in ophthalmology: the controversy moves forward.
    Gillies MC
    Clin Exp Ophthalmol; 2010 May; 38(4):333-4. PubMed ID: 20642588
    [No Abstract]   [Full Text] [Related]  

  • 13. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M; Sharma S
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
    Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
    [No Abstract]   [Full Text] [Related]  

  • 15. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on 'Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial'.
    Fayers T
    Eye (Lond); 2011 Jun; 25(6):820; author reply 820. PubMed ID: 21350573
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost comparison of ranibizumab and bevacizumab.
    Jackson TL; Kirkpatrick L
    BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536
    [No Abstract]   [Full Text] [Related]  

  • 18. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label prescribing in macular degeneration.
    McCartney M
    BMJ; 2011 Oct; 343():d6778. PubMed ID: 22012651
    [No Abstract]   [Full Text] [Related]  

  • 20. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.